David Spigel, MD
Sarah Cannon announced the promotion of David Spigel, MD, as Chief Scientific Officer. The new appointment supports the continuous expansion of clinical research and drug development programs, which provides patients with access to novel therapies at the earliest stages.
As Chief Scientific Officer, Dr. Spigel will oversee the development and operations of Sarah Cannon’s clinical research program and work with research physician leaders as well as biotechnology and pharma companies to ensure the latest innovative treatments are available to patients. Dr. Spigel, who joined Sarah Cannon as Director of the Lung Cancer Research Program, has played a significant role in the development of immunotherapies and other targeted medicines in clinical trials at Sarah Cannon, which have led to new drug approvals.
“For more than 10 years, David has been instrumental in bringing the latest targeted therapies to patients through our lung cancer research program,” said Howard A. “Skip” Burris III, MD, Sarah Cannon’s Chief Medical Officer and President of Clinical Operations. “With his insight and expertise, we have been able to make great strides in advancing the standard of care for patients across tumor types. Under his leadership, we look forward to continuing to enhance our clinical trial offerings and drug development program to further our mission of advancing therapies for patients.”
In addition to his new responsibilities, Dr. Spigel will continue to care for patients in a clinical setting.
Dr. Spigel received his medical degree from The University of Tennessee in Memphis. After completing an internal medicine and chief residency at Indiana University Medical Center, he completed a fellowship in hematology/oncology at the Dana-Farber Cancer Institute. He is board certified in medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC. ■
